ImmunityBio stock tumbles after glioblastoma update; what to watch before Monday
New York, Jan 25, 2026, 05:38 EST — Market closed ImmunityBio, Inc. (IBRX) shares closed Friday down 12.1% at $6.45, having traded as high as $7.88 and as low as $6.43 amid heavy volume. (Yahoo Finance) This move is significant since the stock’s been riding momentum, but Friday’s pullback hands control back to next week’s data releases. Monday’s open will reveal if dip buyers return or decide to sit it out. On Friday, the company highlighted new Phase 2 data from its QUILT-3.078 trial targeting recurrent or progressive glioblastoma, a tough-to-treat brain cancer. ImmunityBio reported that median overall survival was